Literature DB >> 10534335

Natural history of liver disease in cystic fibrosis.

A Lindblad1, H Glaumann, B Strandvik.   

Abstract

The median age of the population with cystic fibrosis (CF) has increased worldwide, which has led to the suggestion that the prevalence of liver disease would increase. The aim of this study was to evaluate the natural history of CF-associated liver disease over a 15-year period in a well-controlled population of patients with CF. During the years 1976 through 1993, 124 patients were followed up by yearly liver function tests (LFTs). Fifteen patients were followed up with liver biopsies throughout the whole study period. More than 50% of the patients had pathological LFTs in infancy, later being normalized. Approximately 25% of children 4 years of age or older had biochemical markers of liver disease during the study period. In about 10% of the patients, cirrhosis or advanced fibrosis was confirmed at biopsy and 4% of patients had cirrhosis with clinical liver disease. Severe liver disease developed mainly during prepuberty and puberty. Of the 15 patients prospectively followed up with liver biopsies, only 3 had progressive fibrosis. No specific risk factor was identified, but deficiency of essential fatty acids was found more often in patients with marked steatosis (P <.05). No patient developed clinical liver disease in adulthood and the histological changes in the liver biopsies were usually not progressive. Liver disease was no more frequent at the end of the study period although the median age of the patient population had increased. Modern treatment might positively influence liver disease because it seemed less common, less progressive, and less serious than previously reported.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534335     DOI: 10.1002/hep.510300527

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  63 in total

1.  The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis.

Authors:  M Gabolde; D Hubert; M Guilloud-Bataille; C Lenaerts; J Feingold; C Besmond
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

Review 2.  The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease.

Authors:  Louise Stewart
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

Review 3.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

4.  Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.

Authors:  Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

5.  Multidisciplinary Treatment of Cystic Fibrosis-Related Recurrent Pyogenic Cholangitis (CF-RPC).

Authors:  James Buxbaum; Nancy Nguyen; Sujit Kulkarni; Suzanne Palmer; Adupa Rao; Robert Selby
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

6.  Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study.

Authors:  Marilyn J Siegel; A Jay Freeman; Wen Ye; Joseph J Palermo; Jean P Molleston; Shruti M Paranjape; Janis Stoll; Daniel H Leung; Prakash Masand; Boaz Karmazyn; Roger Harned; Simon C Ling; Oscar M Navarro; Wikrom Karnsakul; Adina Alazraki; Sarah Jane Schwarzenberg; Frank Glen Seidel; Alex Towbin; Estella M Alonso; Jennifer L Nicholas; Karen F Murray; Randolph K Otto; Averell H Sherker; John C Magee; Michael R Narkewicz
Journal:  J Pediatr       Date:  2020-02-12       Impact factor: 4.406

7.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.

Authors:  Wen Ye; Michael R Narkewicz; Daniel H Leung; Wikrom Karnsakul; Karen F Murray; Estella M Alonso; John C Magee; Sarah Jane Schwarzenberg; Alexander Weymann; Jean P Molleston
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

8.  STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers.

Authors:  Michael Torbenson; Shi Qi Yang; Hui Zhi Liu; Jiawen Huang; Wesley Gage; Anna Mae Diehl
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 9.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

10.  Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis.

Authors:  Daniel H Leung; Wen Ye; Jean P Molleston; Alexander Weymann; Simon Ling; Shruti M Paranjape; Rene Romero; Sara Jane Schwarzenberg; Joseph Palermo; Estella M Alonso; Karen F Murray; Bruce C Marshall; Averell H Sherker; Marilyn J Siegel; Rajesh Krishnamurthy; Roger Harned; Boaz Karmazyn; John C Magee; Michael R Narkewicz
Journal:  J Pediatr       Date:  2015-08-05       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.